Arrowhead Pharmaceuticals announced that its drug Redemplo® (Plozasiran) has received marketing authorization from the European Commission for lowering triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS).
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
UBS warns: US midterm elections may cause severe market volatility, current period is the "calm before the storm"
The chief economist at UBS has issued a warning that September to October has been the most volatile period of the year since 1928, with the effect especially pronounced during midterm election years. The betting odds for Senate control are close to fifty-fifty. Historical data shows that the S&P 500 typically declines before the elections, but posts an average return of about 14% by the following March.
Federal Reserve: Policy path reshaped – Rabobank
10-Yr Benchmark Govt Yields - U.S. vs Other Nations
10-Yr Benchmark Govt Yields - Germany vs Other Nations
Crypto prices
More
